Ajay Varanasi, MD
Endocrinology, Diabetes & Metabolism · St Petersburg, FLNPI 1104982420
Payments from drug & device makers
Across 454 payments — averaging $363.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$51K
- Ascendis Pharma Endocrinology Inc$50K
- Dexcom, Inc.$36K
- Lilly USA, LLC$10K
- Boehringer Ingelheim$10K
- AstraZeneca$5K
- plus $3K from 33 others
What the payments were for
- Consulting fees$2,9252%
- Speaking & faculty fees$137,15986%
- Travel & lodging$9,8396%
- Food & beverage$9,5946%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 112 | $51,325 |
| Ascendis Pharma Endocrinology Inc | 48 | $50,396 |
| Dexcom, Inc. | 65 | $35,744 |
| Lilly USA, LLC | 48 | $9,824 |
| Boehringer Ingelheim | 25 | $9,820 |
| AstraZeneca(2 entities) | 22 | $4,720 |
| Abbott | 16 | $817 |
| Tandem Diabetes Care, Inc. | 19 | $312 |
| Medtronic(2 entities) | 27 | $285 |
| Insulet Corporation | 7 | $195 |
| Amgen(2 entities) | 11 | $186 |
| Sanofi-aventis U.S. LLC | 8 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Novartis | 4 | $90 |
| Xeris Pharmaceuticals, Inc. | 4 | $85 |
| BETA Bionics, Inc. | 3 | $85 |
| Bayer | 3 | $66 |
| RGH Enterprises LLC | 1 | $63 |
| Corcept Therapeutics | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| AbbVie | 2 | $44 |
| Globus Medical | 2 | $43 |
| Ascensia Diabetes Care US Inc. | 2 | $43 |
| Merck | 3 | $43 |
| Lifescan, Inc. | 2 | $40 |
| Nevro Corp. | 2 | $36 |
| Sequel Med Tech, LLC | 1 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Cequr Corporation | 1 | $27 |
| Renalytix AI, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| IBSA Pharma Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Valeritas, Inc. | 1 | $17 |
| Companion Medical, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Vivus LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yorvipath$38,997
- DEXCOM G7 GSS (161)$35,069
- Ozempic$21,870
- JARDIANCE$18,563
- Tresiba$17,898
- DEXCOM STELO GLUCOSE BIOSENSOR$8,281
- FARXIGA$4,325
- RYBELSUS$2,749
- FreeStyle Libre 2$397
- NATPARA (PARATHYROID HORMONE)$125
How this compares
$164,917 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 729 | $1,142,939 |
| MounjaroTirzepatide | 434 | $709,220 |
| TrulicityDulaglutide | 351 | $573,343 |
| JardianceEmpagliflozin | 362 | $465,850 |
| Tresiba Flextouch U-200Insulin Degludec | 255 | $280,073 |
| FarxigaDapagliflozin Propanediol | 167 | $207,272 |
| JanuviaSitagliptin Phosphate | 130 | $156,350 |
| Tresiba Flextouch U-100Insulin Degludec | 196 | $145,004 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $106,514 |
| RybelsusSemaglutide | 31 | $81,338 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $80,602 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $75,186 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 58 | $71,934 |
| Humalog Kwikpen U-200Insulin Lispro | 48 | $55,233 |
| Humulin R U-500Insulin Regular, Human | 26 | $54,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp, Tresiba | $51,325 | $1,308,620890 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $9,824 | $1,307,201855 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $9,820 | $542,920426 claims |
| AstraZenecaFarxiga | $4,720 | $207,272167 claims |
| MerckJanuvia, Janumet | $43 | $175,062141 claims |
| BayerKerendia | $66 | $32,59623 claims |
| AbbVieSynthroid | $44 | $28,440279 claims |
| Sanofi-aventis U.S. LLCLantus | $179 | $12,68639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in St Petersburg
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.